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j.jtcvs.2012.09.048TABLE 1. Characteristics of patients treated with bivalirudin after cardiac surgery
Before
(2004-2006)
After
(2007-2010)
Thrombocytopenia 15.1%
463/3065
14.5%
476/3288
DTI use in patients with thrombocytopenia 17.5%
81/463
23.1%
110/476
HITTS (per decreased platelets) 4.3%
20/463
5.5%
26/476
HITTS (per total adult patients) 0.7%
20/3065
0.8%
26/3288
HITTS mortality 60.0%
12/20
23.0%
6/26
Thrombocytopenia is defined as a 50% decrease in platelets from preoperative baseline by 24 hours after cardiopul-
monary bypass. Mortality is defined as death within index admssion. DTI, Direct thrombin inhibitor; HITTS,
heparin-induced thrombocytopenia and thrombosis syndrome.AORTIC ARCH INTERRUPTION
WITHOUT DUCTUS
ARTERIOSUS AND NO
VENTRICULAR SEPTAL
DEFECT
To the Editor:
We read the interesting case report
by Cazavet and associates1 on ‘‘an in-
fant with a previously unrecorded type
of aortic arch interruption.’’ However,
similar types of aortic arch interrup-
tion without ductus arteriosus and
without ventricular septal defect, al-
though rare, have been previously de-
scribed since 1964.2-6 The common
features of these unusual patients
were the longevity up to adolescence
with no severe symptoms and
the presence of extensive collateral
circulation supplying the descending
aorta.2-6 Surgical treatment was also
reported in relation to the various
anatomic patterns.2-6 In the field of
pediatric cardiology, sometimes some
old scientific papers can represent
important sources of knowledge.
The interesting new aspect de-
scribed by Cazavet and associates1 is
the association with del 22q11 and
the relative embryogenetic implica-
tions that expand the spectrum
of cardiovascular defects of this
syndrome.
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MANAGEMENT OF
HEPARIN-INDUCED
THROMBOCYTOPENIA IN
PATIENTS AFTER CARDIAC
SURGERY
To the Editor:
In a recent publication, Demma,
Paciullo, and Levy1 evaluated the rec-
ognition and treatment of heparin-
induced thrombocytopenia (HIT) in
patients after cardiothoracic surgery
using the direct thrombin inhibitor
(DTI) argatroban. We agree that the
detection and management of HIT in
patients who have had cardiac surgery
is of clinical importance, and we haveof Thoracic and Cardiovascular Surgeused a similar method of HIT identifi-
cation and treatment with the DTI
bivalirudin.
Our familiarity with the use of biva-
lirudin was heightened after our par-
ticipation in the CHOOSE-ON trial
published in 2007, which evaluated
the use of this DTI during cardiopul-
monary bypass in patients having car-
diac surgery.2 Since then, we have
standardized our method of identify-
ing HIT patients postoperatively and
treating them with bivalirudin. To de-
tect HIT, we use a method similar to
that of Demma, Paciullo, and Levy1
in which patients who score in the
moderate range on the 4-Ts schema3
are subjected to a platelet factor 4/
heparin immunoassay. Occasionally,
we will also confirm the diagnosis
with a serotonin release assay. To
then distinguish HIT from hemodilu-
tion or other causes of thrombocyto-
penia, we also categorize the patterns
of platelet counts as outlined by Pou-
plard and colleagues.4
Our standardization of detection
methods did not alter the number of
patients who received a diagnosis of
HIT (14.5% compared with 15.1%
before 2007). However, we did see
an increased rate in the use of
bivalirudin to treat thrombocytopenia
(23.1% compared with 17.5%)
(Table 1). This suggests that our stan-
dardization procedures may have re-
sulted in earlier identification and
medical management of HIT.ry c Volume 145, Number 1 311
